Atlas Trials

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients

Clinical trial NCT03671044 · RECRUITING

Trial details

NCT number
NCT03671044
Sponsor
Jina Pharmaceuticals Inc.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Triple Negative Breast Cancer
Start date
2018-07-10
Primary completion
2025-05-31
Enrollment
657

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.